This protocol covers primary male hypogonadism in men who present with both low serum testosterone and erectile dysfunction. The coexistence of these findings defines a specific clinical situation that requires a coordinated, stepwise approach rather than addressing either problem in isolation.
In hypogonadal men, difficulty achieving or maintaining an erection is a recognised and clinically significant comorbidity. When low testosterone and erectile dysfunction occur together, the choice and sequence of therapeutic interventions is guided by both conditions simultaneously.
The regimen centres on a phosphodiesterase type 5 inhibitor as a primary component. When response is insufficient, a further step is taken. The complete protocol — including criteria for escalation, specific agents, and sequencing — is available in the full structured regimen below.
The primary goal is improvement in erectile function. A meaningful response may take up to six months to become apparent, and this timeline should inform follow-up planning.
In hypogonadal men with erectile dysfunction start with a phosphodiesterase type 5 inhibitor (PDE5I) as first line treatment and add testosterone in case of a poor response to PDE5I treatment.
Changes in erectile function and ejaculation may require up to six months.
View source ↗